124 related articles for article (PubMed ID: 2543918)
1. Dopamine and memory function in Parkinson's disease.
Mohr E; Fabbrini G; Williams J; Schlegel J; Cox C; Fedio P; Chase TN
Mov Disord; 1989; 4(2):113-20. PubMed ID: 2543918
[TBL] [Abstract][Full Text] [Related]
2. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
[TBL] [Abstract][Full Text] [Related]
3. Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease.
Bravi D; Anderson JJ; Dagani F; Davis TL; Ferrari R; Gillespie M; Chase TN
Mov Disord; 1992; 7(3):228-31. PubMed ID: 1620140
[TBL] [Abstract][Full Text] [Related]
4. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
5. Effect of controlled-release carbidopa/levodopa on motor performance in advanced Parkinson's disease.
Rondot P; Ziegler M; Aymard N; Teinturier A
Neurology; 1989 Nov; 39(11 Suppl 2):74-7; discussion 95. PubMed ID: 2586765
[TBL] [Abstract][Full Text] [Related]
6. Off-period screaming accompanying motor fluctuations in Parkinson's disease.
Steiger MJ; Quinn NP; Toone B; Marsden CD
Mov Disord; 1991; 6(1):89-90. PubMed ID: 2005932
[No Abstract] [Full Text] [Related]
7. Recall and recognition memory in patients with Alzheimer's and Parkinson's diseases.
Helkala EL; Laulumaa V; Soininen H; Riekkinen PJ
Ann Neurol; 1988 Aug; 24(2):214-7. PubMed ID: 3178177
[TBL] [Abstract][Full Text] [Related]
8. Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease.
Lewis SJ; Slabosz A; Robbins TW; Barker RA; Owen AM
Neuropsychologia; 2005; 43(6):823-32. PubMed ID: 15716155
[TBL] [Abstract][Full Text] [Related]
9. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations.
Deleu D; Jacques M; Michotte Y; Ebinger G
Neurology; 1989 Nov; 39(11 Suppl 2):88-92; discussion 95. PubMed ID: 2685654
[TBL] [Abstract][Full Text] [Related]
10. Rationale for continuous dopaminomimetic therapy of Parkinson's disease.
Chase TN; Baronti F; Fabbrini G; Heuser IJ; Juncos JL; Mouradian MM
Neurology; 1989 Nov; 39(11 Suppl 2):7-10; discussion 19. PubMed ID: 2685653
[TBL] [Abstract][Full Text] [Related]
11. Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease.
Feldman RG; Mosbach PA; Kelly MR; Thomas CA; Saint Hilaire MH
Neurology; 1989 Nov; 39(11 Suppl 2):96-101; discussion 105. PubMed ID: 2685655
[TBL] [Abstract][Full Text] [Related]
12. High-speed memory scanning in Parkinson's disease: adverse effects of levodopa.
Poewe W; Berger W; Benke T; Schelosky L
Ann Neurol; 1991 Jun; 29(6):670-3. PubMed ID: 1892368
[TBL] [Abstract][Full Text] [Related]
13. The role of dopamine in cognitive sequence learning: evidence from Parkinson's disease.
Shohamy D; Myers CE; Grossman S; Sage J; Gluck MA
Behav Brain Res; 2005 Jan; 156(2):191-9. PubMed ID: 15582105
[TBL] [Abstract][Full Text] [Related]
14. Bilateral subthalamotomy in Parkinson's disease: initial and long-term response.
Alvarez L; Macias R; Lopez G; Alvarez E; Pavon N; Rodriguez-Oroz MC; Juncos JL; Maragoto C; Guridi J; Litvan I; Tolosa ES; Koller W; Vitek J; DeLong MR; Obeso JA
Brain; 2005 Mar; 128(Pt 3):570-83. PubMed ID: 15689366
[TBL] [Abstract][Full Text] [Related]
15. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease.
Fera F; Nicoletti G; Cerasa A; Romeo N; Gallo O; Gioia MC; Arabia G; Pugliese P; Zappia M; Quattrone A
Brain Res Bull; 2007 Sep; 74(1-3):75-83. PubMed ID: 17683792
[TBL] [Abstract][Full Text] [Related]
16. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
Metman LV; Hoff J; Mouradian MM; Chase TN
Mov Disord; 1994 Jul; 9(4):463-5. PubMed ID: 7969216
[TBL] [Abstract][Full Text] [Related]
17. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.
Olanow CW; Fahn S; Muenter M; Klawans H; Hurtig H; Stern M; Shoulson I; Kurlan R; Grimes JD; Jankovic J
Mov Disord; 1994 Jan; 9(1):40-7. PubMed ID: 8139604
[TBL] [Abstract][Full Text] [Related]
18. Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies.
Mouradian MM; Juncos JL; Fabbrini G; Chase TN
Ann Neurol; 1987 Oct; 22(4):475-9. PubMed ID: 3435068
[TBL] [Abstract][Full Text] [Related]
19. [Usefulness of increasing the proportion of carbidopa to levodopa in the long-term treatment of Parkinson's disease].
Bermejo Pareja F; Martínez-Martín P
Med Clin (Barc); 1984 Feb; 82(7):305-10. PubMed ID: 6717135
[No Abstract] [Full Text] [Related]
20. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]